Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:37 2024-05-17 am EDT			5-day change	1st Jan Change
5,531 ^JPY	+0.89%		+2.71%	+42.85%

May. 15	Merck to present new oncology data	CF
May. 15	IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	MT

Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025

April 25, 2024 at 12:00 am EDT

Daiichi Sankyo Company, Limited provided dividend guidance of JPY 30.00 per share for full Fiscal Ending March 31, 2025.

Latest news about Daiichi Sankyo Co., Ltd.

Merck to present new oncology data	May. 15	CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	May. 15	MT
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	May. 07	RE
Japan's Nikkei climbs on Fed rate-cut outlook, tech boost	May. 06	RE
Remsons, Daiichi Infotainments Form Joint Venture	Apr. 30	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	Apr. 29	MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	Apr. 29	CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	Apr. 29	AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	Apr. 29	MT
Hipgnosis Songs Fund backs new Blackstone bid	Apr. 29	AN
Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	Apr. 25	MT
AstraZeneca upbeat as cancer drugs underpin sales growth	Apr. 25	AN
Transcript : Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024	Apr. 25
Daiichi Sankyo Company, Limited Announces Dividend for the Year Ended March 31, 2024, Payable on June 18, 2024 and Provides Dividend Guidance for Second Quarter of Fiscal Ending March 31, 2025	Apr. 25	CI
Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025	Apr. 25	CI
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	Apr. 25	CI
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.	Apr. 25	CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.	Apr. 24	CI
Middle East Tensions Dent Asian Stock Markets	Apr. 19	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	Apr. 08	MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	Apr. 08	MT
AstraZeneca: US approval extended for Enhertu	Apr. 08	CF
AstraZeneca hails neurological data for Ultomiris, Soliris	Apr. 08	AN

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5,531 JPY

Average target price

5,853 JPY

Spread / Average Target

+5.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+42.85%	68.21B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025

Latest news about Daiichi Sankyo Co., Ltd.

Chart Daiichi Sankyo Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Daiichi Sankyo Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals